Published in J Immunol on February 01, 1992
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A (2004) 1.62
Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol (2001) 1.62
T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med (1995) 1.44
Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med (1995) 1.37
pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J (1992) 1.36
Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr Protoc Immunol (2013) 1.24
Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. Proc Natl Acad Sci U S A (1994) 1.15
Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med (1994) 1.06
Long-lived complexes between peptide and class II major histocompatibility complex are formed at low pH with no requirement for pH neutralization. J Exp Med (1992) 1.02
Enhancement of peptide antigen presentation by a second peptide. Proc Natl Acad Sci U S A (1993) 0.97
A structural transition in class II major histocompatibility complex proteins at mildly acidic pH. J Exp Med (1996) 0.97
Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. Proc Natl Acad Sci U S A (1997) 0.95
Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-Au, which confers susceptibility to experimental allergic encephalomyelitis. Mol Med (1996) 0.92
Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. J Exp Med (1996) 0.92
Epitope-specific enhancement of antigen presentation by invariant chain. J Exp Med (1993) 0.92
High-throughput engineering and analysis of peptide binding to class II MHC. Proc Natl Acad Sci U S A (2010) 0.91
Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system. Proc Natl Acad Sci U S A (1994) 0.90
The stimulation of low-affinity, nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope. J Exp Med (1999) 0.88
FcepsilonRI-mediated antigen endocytosis turns interferon-gamma-treated mouse mast cells from inefficient into potent antigen-presenting cells. Immunology (1999) 0.81
A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11. Proc Natl Acad Sci U S A (1999) 0.81
Membrane interactions influence the peptide binding behavior of DR1. J Exp Med (1994) 0.80
Assessing the binding of four Plasmodium falciparum T helper cell epitopes to HLA-DQ and induction of T-cell responses in HLA-DQ transgenic mice. Infect Immun (2000) 0.80
MHC class II-bound self-peptides can be effectively separated by isoelectric focusing and bind optimally to their MHC class II restriction elements around pH 5.0. Immunology (1994) 0.78
pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity. Sci Rep (2015) 0.76
Role of polymorphic residues of human leucocyte antigen-DR molecules on the binding of human immunodeficiency virus peptides. Immunology (1996) 0.76
Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci U S A (2006) 10.24
Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation. J Exp Med (1971) 8.22
Immunoglobulins on the surface of lymphocytes. II. The bone marrow as the main source of lymphocytes with detectable surface-bound immunoglobulin. J Exp Med (1971) 5.43
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest (1971) 4.98
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics (1999) 4.88
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science (1990) 4.45
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol (1984) 3.72
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 3.38
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J Exp Med (1974) 3.21
Structure and function of immunoglobulin A. Prog Allergy (1972) 3.14
Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison. J Immunol (1982) 3.08
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med (1977) 2.98
A subclass of human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking heavy and light chains. J Exp Med (1968) 2.98
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Ice nucleation by particles immersed in supercooled cloud droplets. Chem Soc Rev (2012) 2.74
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med (1973) 2.68
Immunological self, nonself discrimination. Science (1987) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry (1996) 2.51
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol (1970) 2.38
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Thymus-derived (T) cell immunoglobulins. Presence of a receptor site for IgG and absence of large amounts of "buried" Ig determinants on T cells. J Exp Med (1972) 2.35
Immunoglobulins on the surface of lymphocytes. 3. Bursal origin of surface immunoglobulins on chicken lymphocytes. J Immunol (1971) 2.33
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
A new mouse immunoglobulin: IgG3. J Exp Med (1971) 2.27
Requirements for the processing of antigens by antigen-presenting B cells. I. Functional comparison of B cell tumors and macrophages. J Immunol (1982) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cryoimmunoglobulins. Semin Hematol (1973) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry (1999) 2.14
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
B cells as antigen-presenting cells: the requirement for B cell activation. J Immunol (1983) 1.93
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J Immunol (1985) 1.91
Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol (1989) 1.85
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol (2000) 1.84
Studies on receptors for IgG on epithelial cells of the rat intestine. J Immunol (1977) 1.82
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A (1974) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
Sharing of individual antigenic determinants between a gamma G and a gamma M protein in the same myeloma serum. Proc Soc Exp Biol Med (1970) 1.79
Studies on the structure of mouse gamma-A myeloma proteins. Biochemistry (1968) 1.78
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol (1991) 1.75